Inovio provides update on covid-19 heterologous booster vaccine candidate, ino-4800

Plymouth meeting, pa. , oct. 27, 2022 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and prevent infectious diseases, cancer, and diseases associated with hpv, today announced that it has discontinued its internally funded efforts to develop ino-4800 as a covid-19 heterologous booster vaccine.

INO Ratings Summary

INO Quant Ranking